Claritev Return on Equity

Claritev (CTEV) currently reports a ROE of 79.38%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Claritev's ROE history and peer comparisons.

Claritev's ROE of 79.38% is higher than the Healthcare sector average of 13.1%. That is roughly 505.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Claritev's current 79.38% should be judged against Healthcare norms (sector average: 13.1%) and against CTEV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 79.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Claritev, and consider following CTEV for alerts when major investors trade the stock.

Claritev is classified in the Healthcare sector. On ROE, it currently shows 79.38% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTEV with unrelated industries.